Paper30450666
Recent clinical trends in Toll-like receptor targeting therapeutics.
Anwar MA and 3 others. Med Res Rev, 2019. Cited by 230 papers, by iCite.
Cite this record
ConductScience Library. Recent clinical trends in Toll-like receptor targeting therapeutics. Papers, record 30450666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30450666
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Molecular Targeted Therapy | Major topic |
| Toll-Like Receptors | Major topic |
| Adjuvants, Immunologic | |
| Animals | |
| Clinical Trials as Topic | |
| Disease | |
| Humans | |
| Ligands | |
| Signal Transduction |
Source PubMed
References170
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27742543 | Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. | Immunity | 2016 | https://conductscience.org/library/papers/27742543 | PubMed |
| 2 | 22444240 | Regulation of B-cell responses by Toll-like receptors. | Immunology | 2012 | https://conductscience.org/library/papers/22444240 | PubMed |
| 3 | 11037875 | Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. | Arthritis Rheum | 2000 | https://conductscience.org/library/papers/11037875 | PubMed |
| 4 | 23934186 | The Yin and Yang of Toll-like receptors in cancer. | Oncogene | 2014 | https://conductscience.org/library/papers/23934186 | PubMed |
| 5 | 18701762 | The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. | Oncologist | 2008 | https://conductscience.org/library/papers/18701762 | PubMed |
| 6 | 25093709 | Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of naïve CD4+ T cells from allergic patients. | Allergy | 2014 | https://conductscience.org/library/papers/25093709 | PubMed |
| 7 | 21674704 | Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. | Inflamm Bowel Dis | 2011 | https://conductscience.org/library/papers/21674704 | PubMed |
| 8 | 19944565 | Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. | J Autoimmun | 2010 | https://conductscience.org/library/papers/19944565 | PubMed |
| 9 | 22142805 | Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. | NCHS Data Brief | 2011 | https://conductscience.org/library/papers/22142805 | PubMed |
| 10 | 25667264 | Toll-Like receptor 2 (TLR2) and TLR9 play opposing roles in host innate immunity against Salmonella enterica serovar Typhimurium infection. | Infect Immun | 2015 | https://conductscience.org/library/papers/25667264 | PubMed |
| 11 | 27612280 | RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. | Cancer Treat Rev | 2016 | https://conductscience.org/library/papers/27612280 | PubMed |
| 12 | 15001781 | A toll-like receptor that prevents infection by uropathogenic bacteria. | Science | 2004 | https://conductscience.org/library/papers/15001781 | PubMed |
| 13 | 24894651 | Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). | Invest New Drugs | 2014 | https://conductscience.org/library/papers/24894651 | PubMed |
| 14 | 19917698 | TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. | J Immunol | 2009 | https://conductscience.org/library/papers/19917698 | PubMed |
| 15 | 22521140 | Adjuvants for human vaccines. | Curr Opin Immunol | 2012 | https://conductscience.org/library/papers/22521140 | PubMed |
| 16 | 9875924 | Has the mortality of septic shock changed with time. | Crit Care Med | 1998 | https://conductscience.org/library/papers/9875924 | PubMed |
| 17 | 18199559 | Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. | Cancer Res | 2008 | https://conductscience.org/library/papers/18199559 | PubMed |
| 18 | 10215628 | TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. | Genes Dev | 1999 | https://conductscience.org/library/papers/10215628 | PubMed |
| 19 | 16260493 | TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. | Genes Dev | 2005 | https://conductscience.org/library/papers/16260493 | PubMed |
| 20 | 18029230 | Signaling to NF-kappaB by Toll-like receptors. | Trends Mol Med | 2007 | https://conductscience.org/library/papers/18029230 | PubMed |
Cited by151
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 230 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42327785 | Toll-like receptors: versatile players in tumor. | Front Immunol | 2026 | https://conductscience.org/library/papers/42327785 | PubMed |
| 42213280 | TLR ligands as immunomodulators: mechanistic insights and therapeutic potential in infectious and inflammatory diseases. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42213280 | PubMed |
| 41793185 | Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41793185 | PubMed |
| 41787453 | Neutrophil extracellular traps-associated candidate genes in IgA vasculitis: an exploratory multi-omics analysis integrating transcriptomics and Mendelian randomization. | Pediatr Rheumatol Online J | 2026 | https://conductscience.org/library/papers/41787453 | PubMed |
| 41706189 | Immunoinformatics-guided design of a multi-epitope vaccine targeting the envelopment polyprotein of oropouche virus. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/41706189 | PubMed |
| 41597427 | Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/41597427 | PubMed |
| 41417465 | Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives. | J Med Chem | 2026 | https://conductscience.org/library/papers/41417465 | PubMed |
| 41322409 | Extracellular microRNAs modulate human microglial function through TLR8. | Front Immunol | 2025 | https://conductscience.org/library/papers/41322409 | PubMed |
| 41158497 | Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population. | ERJ Open Res | 2025 | https://conductscience.org/library/papers/41158497 | PubMed |
| 40891672 | Toll-like receptors (TLRs) in the trained immunity era. | Elife | 2025 | https://conductscience.org/library/papers/40891672 | PubMed |
| 40837119 | Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines. | Nano Res | 2025 | https://conductscience.org/library/papers/40837119 | PubMed |
| 40573201 | Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573201 | PubMed |
| 40396589 | Exploring the Role of Pattern Recognition Receptors as Immunostimulatory Molecules. | Immun Inflamm Dis | 2025 | https://conductscience.org/library/papers/40396589 | PubMed |
| 40163200 | Noncoding RNA (ncRNA)-mediated regulation of TLRs: critical regulator of inflammation in tumor microenvironment. | Med Oncol | 2025 | https://conductscience.org/library/papers/40163200 | PubMed |
| 39982077 | Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action. | Clin Microbiol Rev | 2025 | https://conductscience.org/library/papers/39982077 | PubMed |
| 39947253 | The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/39947253 | PubMed |
| 39827246 | TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity. | NPJ Vaccines | 2025 | https://conductscience.org/library/papers/39827246 | PubMed |
| 39769150 | Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769150 | PubMed |
| 39684260 | Senescent T Cells: The Silent Culprit in Acute Myeloid Leukemia Progression? | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39684260 | PubMed |
| 39655168 | Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology. | ERJ Open Res | 2024 | https://conductscience.org/library/papers/39655168 | PubMed |
Genes86
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30450666
GET https://conductscience.org/api/papers/v1/30450666/references?page=2